ABSTRACTS Archives - Page 13 of 17

O.01 Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamide-treated Patients with Castration-Resistant Prostate Cancer

BJMO - 2017, issue 3, february 2017

B. De Laere PhD, P. Van Oyen , C. Ghysel , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert MD, J. Ampe , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , S. Oeyen , V. Van Dam , A. Brouwer , G. Van Den Eynden MD, PhD, A. Rutten MD, J. Vandebroek , S. Van Laere PhD, L. Dirix MD

O.02 Immuno-FIELT: The role of Tumor Infiltrating Lymphocytes and PD-L1 expression in NSCLC adenocarcinoma in little to non-smokers and its relationship with driver mutations and clinical outcome parameters

BJMO - 2017, issue 3, february 2017

S. Mignon MD

O.03 Identification of candidate breast cancer predisposition genes by sequencing extended panel of 492 cancer associated genes in BRCA1/2 negative probands

BJMO - 2017, issue 3, february 2017

R.B. Shahi MSc, B. Caljon , S. De Brakeleer PhD, L. Decoster MD, PhD, C. Fontaine MD, L. Vanacker MD, M. Vanhoeij , I. Pauwels , M-L. Bonduelle , S. Van Dooren PhD, D. Croes , E. Teugels PhD, J. De Grève MD, PhD

O.04 Type II RAF inhibition causes superior ERK suppression compared to type I RAF inhibition in different BRAF mutant types recurrently found in lung cancer

BJMO - 2017, issue 3, february 2017

A. Noeparast PhD, P. Giron PhD, S. De Brakeleer PhD, U. De Ridder , E. Teugels PhD, J. De Grève MD, PhD

O.05 Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

BJMO - 2017, issue 3, february 2017

L. Buisseret MD, S. Pommey , B. Allard , S. Garaud , M-A. Bergeron , I. Cousineau , L. Ameye , G. Chouinard , H. Duvillier , M. Paesmans , M.J. Piccart-Gebhart MD, K. Willard-Gallo , C. Sotiriou MD, PhD, J. Stagg